One-year treatment with cholecystokinin-octapeptide and secretin: Effects on pancreatic trophism in the rat

István Nagy, T. Takács, Gábor Mohácsi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The effects of long-term administration of cholecystokinin octapeptide (CCK-8) with or without secretin on the pancreas were examined in groups of rats treated with: (1) CCK-8 (1 μg kg-1); (2) secretin + CCK-8 (1 μg kg-1 of each); or (3) saline, administered subcutaneously twice daily for 5 out of 7 days for 6 or 12 months. A number of rats from all groups were studied for: (1) pancreatic size and biochemical composition (n = 6 for each group); (2) pancreatic secretion in the anesthetized state (n = 5 for each group); and (3) pancreatic histology (n = 6 for each group) after a 6-month treatment period. The rest of the animals treated for an additional 6-month period (n = 13 for each group) were examined for pancreatic size and histology. CCK-8 increased the weight of the pancreas and its contents of DNA, protein, trypsinogen, chymotrypsinogen, proelastase, secretory trypsin inhibitor and amylase, but not that of lipase when given for 6 months, whereas administration of secretin + CCK-8 doubled the pancreatic content of lipase and increased all trophic parameters (except the amylase content) over those of CCK-8-treated rats. Maximum pancreatic volume and protein outputs in response to CCK-8 were higher in both of the hormone-treated groups than in the control; the sensitivity to the secretory action of CCK-8 was not altered. Pancreatic mass increased in response to either treatment after 12 months as well. Histological examination did not reveal pancreatic neoplasia in either group. The results indicate that long-term administration of CCK-8 or secretin + CCK-8 in rats results in sustained pancreatic hypertrophy and hyperplasia with secretory hyperfunction with no evidence of neoplastic alterations.

Original languageEnglish
Pages (from-to)77-85
Number of pages9
JournalPharmacological Research
Volume36
Issue number1
DOIs
Publication statusPublished - Jul 1997

Fingerprint

Sincalide
Secretin
Therapeutics
Amylases
Lipase
Pancreas
Histology
Chymotrypsinogen
Trypsinogen
Trypsin Inhibitors
Hypertrophy
Hyperplasia
Proteins
Hormones

Keywords

  • Cholecystokinin
  • Neoplasia
  • Pancreas
  • Rat
  • Secretin

ASJC Scopus subject areas

  • Pharmacology

Cite this

One-year treatment with cholecystokinin-octapeptide and secretin : Effects on pancreatic trophism in the rat. / Nagy, István; Takács, T.; Mohácsi, Gábor.

In: Pharmacological Research, Vol. 36, No. 1, 07.1997, p. 77-85.

Research output: Contribution to journalArticle

@article{6fcdf70461234d3da26a877b2130f849,
title = "One-year treatment with cholecystokinin-octapeptide and secretin: Effects on pancreatic trophism in the rat",
abstract = "The effects of long-term administration of cholecystokinin octapeptide (CCK-8) with or without secretin on the pancreas were examined in groups of rats treated with: (1) CCK-8 (1 μg kg-1); (2) secretin + CCK-8 (1 μg kg-1 of each); or (3) saline, administered subcutaneously twice daily for 5 out of 7 days for 6 or 12 months. A number of rats from all groups were studied for: (1) pancreatic size and biochemical composition (n = 6 for each group); (2) pancreatic secretion in the anesthetized state (n = 5 for each group); and (3) pancreatic histology (n = 6 for each group) after a 6-month treatment period. The rest of the animals treated for an additional 6-month period (n = 13 for each group) were examined for pancreatic size and histology. CCK-8 increased the weight of the pancreas and its contents of DNA, protein, trypsinogen, chymotrypsinogen, proelastase, secretory trypsin inhibitor and amylase, but not that of lipase when given for 6 months, whereas administration of secretin + CCK-8 doubled the pancreatic content of lipase and increased all trophic parameters (except the amylase content) over those of CCK-8-treated rats. Maximum pancreatic volume and protein outputs in response to CCK-8 were higher in both of the hormone-treated groups than in the control; the sensitivity to the secretory action of CCK-8 was not altered. Pancreatic mass increased in response to either treatment after 12 months as well. Histological examination did not reveal pancreatic neoplasia in either group. The results indicate that long-term administration of CCK-8 or secretin + CCK-8 in rats results in sustained pancreatic hypertrophy and hyperplasia with secretory hyperfunction with no evidence of neoplastic alterations.",
keywords = "Cholecystokinin, Neoplasia, Pancreas, Rat, Secretin",
author = "Istv{\'a}n Nagy and T. Tak{\'a}cs and G{\'a}bor Moh{\'a}csi",
year = "1997",
month = "7",
doi = "10.1006/phrs.1997.0210",
language = "English",
volume = "36",
pages = "77--85",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - One-year treatment with cholecystokinin-octapeptide and secretin

T2 - Effects on pancreatic trophism in the rat

AU - Nagy, István

AU - Takács, T.

AU - Mohácsi, Gábor

PY - 1997/7

Y1 - 1997/7

N2 - The effects of long-term administration of cholecystokinin octapeptide (CCK-8) with or without secretin on the pancreas were examined in groups of rats treated with: (1) CCK-8 (1 μg kg-1); (2) secretin + CCK-8 (1 μg kg-1 of each); or (3) saline, administered subcutaneously twice daily for 5 out of 7 days for 6 or 12 months. A number of rats from all groups were studied for: (1) pancreatic size and biochemical composition (n = 6 for each group); (2) pancreatic secretion in the anesthetized state (n = 5 for each group); and (3) pancreatic histology (n = 6 for each group) after a 6-month treatment period. The rest of the animals treated for an additional 6-month period (n = 13 for each group) were examined for pancreatic size and histology. CCK-8 increased the weight of the pancreas and its contents of DNA, protein, trypsinogen, chymotrypsinogen, proelastase, secretory trypsin inhibitor and amylase, but not that of lipase when given for 6 months, whereas administration of secretin + CCK-8 doubled the pancreatic content of lipase and increased all trophic parameters (except the amylase content) over those of CCK-8-treated rats. Maximum pancreatic volume and protein outputs in response to CCK-8 were higher in both of the hormone-treated groups than in the control; the sensitivity to the secretory action of CCK-8 was not altered. Pancreatic mass increased in response to either treatment after 12 months as well. Histological examination did not reveal pancreatic neoplasia in either group. The results indicate that long-term administration of CCK-8 or secretin + CCK-8 in rats results in sustained pancreatic hypertrophy and hyperplasia with secretory hyperfunction with no evidence of neoplastic alterations.

AB - The effects of long-term administration of cholecystokinin octapeptide (CCK-8) with or without secretin on the pancreas were examined in groups of rats treated with: (1) CCK-8 (1 μg kg-1); (2) secretin + CCK-8 (1 μg kg-1 of each); or (3) saline, administered subcutaneously twice daily for 5 out of 7 days for 6 or 12 months. A number of rats from all groups were studied for: (1) pancreatic size and biochemical composition (n = 6 for each group); (2) pancreatic secretion in the anesthetized state (n = 5 for each group); and (3) pancreatic histology (n = 6 for each group) after a 6-month treatment period. The rest of the animals treated for an additional 6-month period (n = 13 for each group) were examined for pancreatic size and histology. CCK-8 increased the weight of the pancreas and its contents of DNA, protein, trypsinogen, chymotrypsinogen, proelastase, secretory trypsin inhibitor and amylase, but not that of lipase when given for 6 months, whereas administration of secretin + CCK-8 doubled the pancreatic content of lipase and increased all trophic parameters (except the amylase content) over those of CCK-8-treated rats. Maximum pancreatic volume and protein outputs in response to CCK-8 were higher in both of the hormone-treated groups than in the control; the sensitivity to the secretory action of CCK-8 was not altered. Pancreatic mass increased in response to either treatment after 12 months as well. Histological examination did not reveal pancreatic neoplasia in either group. The results indicate that long-term administration of CCK-8 or secretin + CCK-8 in rats results in sustained pancreatic hypertrophy and hyperplasia with secretory hyperfunction with no evidence of neoplastic alterations.

KW - Cholecystokinin

KW - Neoplasia

KW - Pancreas

KW - Rat

KW - Secretin

UR - http://www.scopus.com/inward/record.url?scp=0031193271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031193271&partnerID=8YFLogxK

U2 - 10.1006/phrs.1997.0210

DO - 10.1006/phrs.1997.0210

M3 - Article

C2 - 9368919

AN - SCOPUS:0031193271

VL - 36

SP - 77

EP - 85

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1

ER -